Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$18.08 - $23.45 $4,592 - $5,956
-254 Reduced 0.2%
129,918 $2.38 Million
Q2 2023

Aug 14, 2023

SELL
$20.98 - $31.42 $1.73 Million - $2.59 Million
-82,281 Reduced 38.73%
130,172 $2.81 Million
Q1 2023

May 15, 2023

BUY
$27.71 - $40.93 $232,126 - $342,870
8,377 Added 4.1%
212,453 $6.23 Million
Q4 2022

Feb 14, 2023

BUY
$29.75 - $39.26 $4.05 Million - $5.35 Million
136,201 Added 200.66%
204,076 $7.54 Million
Q3 2022

Nov 14, 2022

SELL
$17.15 - $30.92 $533,022 - $960,993
-31,080 Reduced 31.41%
67,875 $1.91 Million
Q2 2022

Aug 15, 2022

BUY
$6.85 - $19.93 $114,018 - $331,734
16,645 Added 20.22%
98,955 $1.91 Million
Q1 2022

May 16, 2022

BUY
$12.85 - $32.9 $1.06 Million - $2.71 Million
82,310 New
82,310 $1.06 Million

Others Institutions Holding AMLX

About Amylyx Pharmaceuticals, Inc.


  • Ticker AMLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,533,200
  • Market Cap $290M
  • Description
  • Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...
More about AMLX
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.